Myriad Genetics Announces Q1 2025 Earnings Call Details

Author: Evelyn Baker Updated: 04-29-2025 09:09 AM

Myriad Genetics' Upcoming Financial Release for Q1 2025

Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent player in the field of molecular diagnostic testing and precision medicine, is set to unveil its first quarter financial results for 2025. The anticipated results will be disclosed on a significant date—May 6, when the market closes, followed by an earnings conference call at 4:30 pm EDT.

Engaging with Investors

During the call, Myriad's management will share an in-depth financial overview, along with a business update highlighting the company's performance. Investors and analysts are encouraged to tune in, as this call will provide valuable insights into the first quarter of 2025 and the strategic direction of the company.

Accessing the Conference Call

For those interested in participating, the conference call will be available live through Myriad's Investor Relations website. A simple registration will grant participants access to a dial-in number and unique PIN needed to join. After the event, there will also be an archived version of the webcast for those unable to attend.

Investor Interactions Scheduled for Q2 2025

In addition to the upcoming earnings call, Myriad plans to be active in the investor arena during the second quarter of 2025. Management has confirmed participation in several key investor healthcare conferences.

Scheduled Conferences

BofA Securities 2025 Health Care Conference – Fireside chat scheduled for May 14 at 3:00 pm EDT.
Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on June 11 at 2:00 pm EDT.

Live and archived webcasts from these presentations will also be available on the same Investor Relations website.

The Role of Myriad Genetics in the Healthcare Sector

Myriad Genetics stands at the forefront of molecular diagnostic testing and precision medicine, committed to enhancing health outcomes internationally. Their offerings include a range of molecular tests designed to assess disease risk and guide treatment decisions in various medical fields. Such innovations not only improve patient care but also have the potential to reduce healthcare costs significantly.

Commitment to Innovation

By developing advanced tests that provide crucial information on disease progression, Myriad Genetics empowers healthcare providers and patients alike. Their technology is crucial across various medical specialties, allowing for tailored treatment plans that enhance patient outcomes.

Contact Information for Investors and Media

For those seeking further information or wishing to engage with the company, Myriad Genetics has designated contacts available for inquiries:

Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact:
Kate Schraml
(224) 875-4493
PR@myriad.com

Frequently Asked Questions

When will Myriad Genetics release its Q1 2025 financial results?

Myriad Genetics will release its financial results on May 6, 2025, after market close.

How can I participate in Myriad's earnings call?

Investors can register through Myriad's Investor Relations website to receive the dial-in information for the earnings call.

What will be discussed during the earnings call?

The management team will provide a financial overview and business update regarding the company's performance during Q1 2025.

Is there a way to access a recording of the earnings call?

Yes, an archived version of the earnings call will be available on Myriad's Investor Relations website shortly after the event.

What investor conferences will Myriad Genetics participate in during Q2 2025?

Myriad plans to participate in the BofA Securities 2025 Health Care Conference and the Goldman Sachs 46th Annual Global Healthcare Conference.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.